NeoGenomics (NEO) AI Stock Analysis
NeoGenomics
(BMV:NEO)
No summary available
NeoGenomics (NEO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 2.26B
- Dividend Yield
- ―
- Average Volume (3M)
- 495
- Price to Earnings (P/E)
- -70.4
- Beta (1Y)
- 0.06
- Revenue Growth
- -0.33%
- EPS Growth
- 74.45%
- Country
- Mexico
- Employees
- 2,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
NeoGenomics Business Overview & Revenue Model
Company Description
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical S...
NeoGenomics Earnings Call Summary
The call was strongly positive, marked by 11% total revenue growth, 29% NGS growth, more than 300 basis points of adjusted gross-margin expansion, 53% adjusted EBITDA growth, and higher 2026 revenue and EBITDA guidance. Management also highlighted expanding MRD reimbursement, payer wins, product upgrades, sales-force investment, and a leadership transition occurring from a position of strength. The principal challenges were declining nonclinical revenue, legacy pharma pressure, near-term unreimbursed MRD testing, temporary receivables and cash-flow effects, and potential PAMA-related EBITDA pressure, but these issues were presented as manageable relative to the company's growth momentum.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
NeoGenomics raised full year '26 revenue guidance to a range of $807 million to $809 million, representing full year revenue growth of approximately 11% at the midpoint, with clinical business growth in the low-teens, NGS revenue growth of more than 25% and approaching approximately $250 million in 2026, no change to PanTracer Liquid or RaDaR ST revenue assumptions, and nonclinical business down low double digits year-over-year; fourth quarter revenue growth is expected to be approximately 11%, adjusted gross margin improvement for the full year well over 150 basis points, implying fourth quarter gross margin of approximately 48%, and full year '26 adjusted EBITDA approximately $60 million, representing year-over-year growth of approximately 40%; AUP growth was guided in the high single digits and volume growth in the low single digits, with volume and AUP expected to track back to the mid-single digit in a normal environment, two additional RaDaR ST indications are expected to receive reimbursement, one potentially by year-end and the other by mid-2027, the heme NGS portfolio is expected to transition to NovaSeq X in the first half of 2027, and pharma could be slightly positive in '27, with legacy pharma a low single-digit kind of decline and net-net slightly up.
NeoGenomics Risk Analysis
NeoGenomics disclosed 43 risk factors in its most recent earnings report. NeoGenomics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksNeoGenomics Peers Comparison
Overall Rating
VCYT78Outperform
DGX76Outperform
LH75Outperform
CSTL70Outperform
GH55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VCYT | 78Outperform | $4.02B | 34.73 | 8.64% | ― | 17.28% | 323.64% |
| DGX | 76Outperform | $27.71B | 24.74 | 15.21% | 1.34% | 9.13% | 17.93% |
| LH | 75Outperform | $29.31B | 29.45 | 11.54% | 0.80% | 6.02% | 19.63% |
| CSTL | 70Outperform | $1.14B | -56.34 | -4.15% | ― | 3.18% | -100.37% |
| GH | 55Neutral | $23.99B | -51.23 | 211.46% | ― | 42.74% | -4.60% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:NEO | NeoGenomics Inc. | 339.00 | 139.00 | 69.50% | |
| LH | Labcorp Holdings Inc. | 361.39 | 106.13 | 41.58% | |
| DGX | Quest Diagnostics | 251.82 | 75.94 | 43.18% | |
| VCYT | Veracyte Inc | 50.01 | 13.56 | 37.20% | |
| GH | Guardant Health | 178.80 | 79.88 | 80.75% | |
| CSTL | Castle Biosciences | 37.16 | 11.17 | 42.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.